- Home
- SI vs GALT Comparison
SI vs GALT Comparison
Compare SI & GALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SI | GALT |
|---|---|---|
| Founded | 2009 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 269.1M | 297.0M |
| IPO Year | N/A | 2008 |
Fundamental Metrics
Financial Performance| Metric | SI | GALT |
|---|---|---|
| Price | $20.99 | $4.00 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 2 |
| Target Price | ★ $20.80 | $8.50 |
| AVG Volume (30 Days) | 148.5K | ★ 1.3M |
| Earning Date | 05-13-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 36.84 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $39.59 | N/A |
| Revenue Next Year | $31.37 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $10.92 | $2.03 |
| 52 Week High | $23.00 | $7.13 |
Technical Indicators
Market Signals| Indicator | SI | GALT |
|---|---|---|
| Relative Strength Index (RSI) | 54.79 | 49.58 |
| Support Level | $12.79 | $2.30 |
| Resistance Level | $22.92 | $4.35 |
| Average True Range (ATR) | 1.58 | 0.52 |
| MACD | -0.17 | -0.11 |
| Stochastic Oscillator | 37.70 | 1.23 |
Price Performance
Historical ComparisonAbout SI Shoulder Innovations Inc.
Shoulder Innovations Inc is a commercial-stage medical technology company exclusively focused on transforming the shoulder surgical care market. It currently offers advanced implant systems for shoulder arthroplasty. Its products include: InSet Total Shoulder Arthroplasty; InSet Reverse Shoulder Arthroplasty; ProVoyance Shoulder Planning Software; and InSet Tray System.
About GALT Galectin Therapeutics Inc.
Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.